Heidelberg, Germany, December 17, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition to the NASDAQ Biotechnology Index will become effective prior to market open on Monday, December 23, 2019.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria.

The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology exchange-traded fund (Nasdaq: IBB). More information about the Index can be found at https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The Company is developing single and combination therapies to treat hematologic and solid tumors. For more information, please visit www.affimed.com.

Affimed Investor and Media Contact:

Gregory Gin, Head of Investor Relations
E-Mail: IR@affimed.com